Panoramic Capital LLC Cuts Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Panoramic Capital LLC reduced its stake in Eli Lilly and Company by 51.5%, now holding 3,724 shares valued at approximately $3.08 million.
• Despite Panoramic's sell-off, other investors have shown increased interest, with Parkman Healthcare Partners LLC raising its stake by 39.2% to nearly 39,191 shares.
• Eli Lilly reported $15.56 billion in revenue for the last quarter, exceeding analyst expectations, and set a full-year 2025 earnings guidance of $21.750-$23.000 EPS.

Panoramic Capital LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 51.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,724 shares of the company's stock after selling 3,957 shares during the period. Eli Lilly and Company comprises about 3.3% of Panoramic Capital LLC's holdings, making the stock its 9th largest position. Panoramic Capital LLC's holdings in Eli Lilly and Company were worth $3,076,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Parkman Healthcare Partners LLC boosted its holdings in Eli Lilly and Company by 39.2% during the 1st quarter. Parkman Healthcare Partners LLC now owns 39,191 shares of the company's stock worth $32,368,000 after acquiring an additional 11,028 shares during the last quarter. Petrus Trust Company LTA purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $425,000. Plancorp LLC grew its position in Eli Lilly and Company by 1.9% during the first quarter. Plancorp LLC now owns 12,823 shares of the company's stock valued at $10,591,000 after buying an additional 237 shares during the period. NFJ Investment Group LLC increased its holdings in Eli Lilly and Company by 73.7% during the first quarter. NFJ Investment Group LLC now owns 24,363 shares of the company's stock worth $20,122,000 after buying an additional 10,337 shares during the last quarter. Finally, Nissay Asset Management Corp Japan ADV raised its position in Eli Lilly and Company by 0.5% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 141,341 shares of the company's stock worth $116,735,000 after acquiring an additional 664 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Finally, Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Price Performance

LLY traded up $11.35 during trading on Tuesday, reaching $749.99. The stock had a trading volume of 2,983,536 shares, compared to its average volume of 4,135,773. The business has a 50-day moving average of $743.02 and a 200-day moving average of $779.63. Eli Lilly and Company has a one year low of $623.78 and a one year high of $942.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $709.83 billion, a PE ratio of 49.02, a PEG ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jamere Jackson bought 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.